findmyKOL

Amy Warriner

Basic profile

University of Alabama at Birmingham

ORCIDNone on fileNPI
RegionBirmingham, AL · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH fundingNot yet indexedWhy? →

Amy Warriner is an Endocrinology/Metabolic physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 49 publications with 1,386 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
49publications

Distinct works indexed by OpenAlex.

1,386citations

Total citations across indexed works.

19h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    47.6%
    GLP-1 receptor agonist21.3%
    Mounjaro41%Trulicity39%Ozempic20%
    Part D28 patients
    Insulin Analog9.6%
    Tresiba Flextouch U-10031%Lantus Solostar25%Novolog Flexpen22%Toujeo Solostar13%Humalog Kwikpen U-1008%
    Part D<11 patients

    + 4 more classes in this area

  • Hormonal (systemic)

    24.6%
    Parathyroid Hormone Analog10.5%
    Forteo100%
    Part D30 patients
    l-Thyroxine10.1%
    Levothyroxine Sodium87%Synthroid13%
    Part D<11 patients

    + 2 more classes in this area

  • Musculoskeletal

    13%
    Bisphosphonate5.4%
    Zoledronic Acid100%
    Part D101 patients
    Bisphosphonates3.8%
    Risedronate Sodium100%
    Part D17 patients

    + 3 more classes in this area

Where care is delivered (Part B)82.9% facility · 17.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”